LATEST NEWS

12/20/2020

“Updates on Colorectal Cancer” Webinar

Iranian Society of Radiation Oncology,ISRO & Actero cooperated to hold a webinar, “Updates On Colorectal Cancer” on December 10th -2020, with the lectures of Dr. Mafi(Radio Oncologist), Dr. Yaghoubi Jouybari(Radio Oncologist) and Dr.Joudi(Radio Oncologists),followed by a discussion panel with presence of Dr.Taghizadeh (Radio Oncologist)& Dr. Motlagh(Radio Oncologist).

At the beginning of mentioned webinar, we were honored to have Dr. Ghavam Nasiri (Head of ISRO) whom pointed out the importance of this webinar.
Actero Company with its products such as Capecitabin ACTe & Irinotecan ACTe tries to be an important part of colorectal cancer patient’s treatment journey.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

12/20/2020

Lung Cancer & COVID-19 Webinar.

Regarding the Importance of experience sharing about Lung cancer patients with COVID-19 complications, a multidisciplinary virtual Meeting was held on December 3rd 2020, with the topic of “Lung Cancer & COVID19” with the presence of Dr. Khosravi (Medical Oncologists), Dr. Seifi (Medical Oncologists), Dr. Salimi (Medical Oncologists), Dr. Kiani (Pulmonologist), Dr. Naseri (Radio Oncologist), Dr. Bakhshayesh karam (Radiologist), Dr. Daneshvar (Thoracic Surgeon).

Erlotinib ACTe & Pemetrexed ACTe are two ACTERO’s products, which has a certain position in lung cancer treatment.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.

Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib.

Therefore, by delivering the drug sample to physicians specializing in this field, treatment coverage began in a number of eligible patients.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Breast Cancer Webinar

Simultaneously with the unveiling of Onkotaxel (Docetaxel of Actero Company), a subspecialized webinar was held on July 23rd with the presence of Dr. Safa Najafi (Medical Oncologist), Dr. Samiei (Radiotherapy Oncologist), Dr. Azimi Nejadan (Surgeon) and Ms. Dr. Ehsani (Pathologist) on August 2.

The webinar discussed the latest updates in breast cancer diagnosis and treatment, with 344 live broadcast participants and 203 replay viewers.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Injection production line opening

After opening and operating the injection drug production line last year and increasing its production capacity in order to expand the product basket portfolio in the New Year, Actero factory, which specializes in the production of cancer drugs, intends to meet the needs of cancer patients in most treatment protocols.

At present, Bortezomib, Pemetrexed , Irinotecan, Gemcitabine, Docetaxel and Carboplatin drugs of Actero Company are available to our dear patients.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Production and launch of Favipiravir and Remdesivir in Actover Pharma group

With continuous monitoring of international research and protocols, it was suggested to produce drugs in the treatment of Covid-19 in the Actover group, as a pioneer in the production of drugs needed in Covid 19, the group unveiled two drugs, Remdesivir and Favipiravir.

It should be noted that these two drugs have entered the official list of drugs in Iran.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Pharmex congress

The presence of Actover Pharmaceutical Group in the second Pharmex exhibition on June 30th to July 2nd at the Olympic Hotel as the main sponsor, as well as participation in scientific workshops.

 

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/20/2020

Multiple Myeloma and COVID 19 Webinar

Holding a subspecialty webinar on multiple myeloma management and Covid 19 on May 21st with the presence of prominent professors of medical oncology from Tehran, Dr. Mousavi, Dr. Razavi, Dr. Shahi, from Rasht, Dr. Najafi, from Isfahan, Dr. Ashrafi, simultaneously with the unveiling Bortezomib Acte was administered.

This webinar talked about how to manage the treatment of patients with multiple myeloma in the epidemic of Covid 19.

 

If you would like more information about this topic, please contact us at news@acteropharma.com

10/10/2020

COVID 19

Actero Company, considering its social responsibility and in order to meet the needs of Covid 19 disease aids, immediately imported the desired items and to some extent met the needs of the dear patients of the country.

So far, more than 4,000 different PCR and antibody tests have been performed for Actover Group colleagues in the pharmaceutical and food sectors, and efforts have been made to ensure the health of the environment by developing care and health protocols.

Actover Group has produced 20,000 personal protective clothing as well as hand sanitizer since March 2020 and has provided it free of charge to doctors, pharmacists and other medical staff in different cities of the country.

If you would like more information about this topic, please contact us at news@acteropharma.com

27/08/2019

ACTERO LAUNCHES IMATINIB ACTE AND NILOTINIB ACTE

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market: Imatinib ACTe 100mg and Nilotinib ACTe 200mg.

Imatinib ACTe 100mg is the generic version of Gleevec, a chemotherapy medication used to treat chronic myelogenous leukemia and acute lymphocytic leukemia that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors, hypereosinophilic syndrome, chronic eosinophilic leukemia, systemic mastocytosis, and myelodysplastic syndrome. Nilotinib ACTe 200mg is the generic version of Tasigna, used for the treatment of imatinib-resistant chronic myelogenous leukemia.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

06/07/2019

WE ARE NOT JUST IMAGINING THE FUTURE – WE DO CREATE IT!

ACTERO pharmaceutical company is honored to announce the launch of its new scientific product in the field, The Journal of Current Oncology!

As the first national English oncology journal, this eclectic review provides you cutting-edge findings in different scopes of clinical oncology collected from top ranking journals and well-known international oncology seminars in order to keep you aware of the recent advancements in the field.
As the medical forefronts of the oncology realm which have always conferred credit to us, we hope such scientific work can open a promising avenue to gain the novel insights in your practice in cancer therapy and also better help us persevere to contribute something elegant to the medical society.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

26/11/2018

ACTERO CELEBRATED ITS OPENING DAY WITH THE PRESENCE OF MINISTER OF HEALTH AND MEDICAL EDUCATION

On 26th November, Dr. Hashemi, Minister of Health, officials of Alborz government and Mine and Trade organization honored Actero with their presence to celebrated its inauguration day. In this ceremony that was held at the plant in Baharestan industrial zone, domestic and foreign authorities and reporters were introduced to Actero’s objectives and potentials and visited its injectable and solid lines.

“All oncology products of Actero is produced under GMP and OEL4 criteria and these drugs are at the level of high quality imported products.”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

27/09/2018

ACTERO ATTENDED THE 4th IRAN PHARMA INTERNATIONAL EXHIBITION

Actero attended the 4th Iran Pharma exhibition held from September 24th to 26th at Grand Mosalla of Tehran.

In this international exhibition, Actero showcased its range of pharmaceutical products in the oncology field to the visitors.

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

Iran Pharma exhibition benefits from the presence of a large number of domestic and foreign companies in the field of pharmaceuticals, raw materials, food and pharmaceutical ingredients, herbal and natural products, cosmetics, care equipment, pharmaceutical equipment and packaging services.

If you would like more information about this topic, please contact us at news@acteropharma.com

10/09/2018

ACTERO WELCOMED LEBANESE REPORTERS TO ITS MANUFACTURING FACILITIES

On 9th September, a media team consisting of 30 reporters from Lebanon came to visit Actero. During this visit, they interviewed Actero specialists and witnessed in person the safety and quality of production lines of Actero.

“We, at Actero, are committed to quality and our manufacturing facility is operating under strict GMP criteria to produce solid and injectable dosages.”

Suresh Sangisetty, Production Manager

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

10/09/2018

AUTHORITIES OF PROVINCIAL GOVERNMENT VISITED ACTERO MANUFACTURING FACILITY

On 4th September authorities of Alborz province government visited the Actero facility. Mr. Najafi, Deputy Minister of Industry, Mr. Shahmoradi, Chairman of Alborz Industry Organization and other officials honored Actero with their presence and visited the facility and its potentials. Earlier this year, the regional government had recognized Actero as an outstanding project.

“Actero is the biggest manufacturer of oncology products in the Middle East and aims to be actively present in both national and international markets.”

Dr. Ravindra Babu, Plant Head

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

01/09/2018

IN A COLLABORATION WITH MAHAK, ACTERO MEMBERS TOOK PART IN A STEM CELL DONATION PROGRAM

Members of Actero family took part in a stem cell donation program by giving a sample of their salvia. The program was executed on 14th August at the company head office by Mahak charity and samples were gathered for submission to Human Leukocyte Antigen bank.

“As a company active in manufacturing oncology products we are well aware of the hardship of cancer treatment; that is why we feel responsible to partake in such programs.”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.
Mahak, the society to support children from cancer, has provided comprehensive coverage and treatment to over 27000 children and their families.

If you would like more information about this topic, please contact us at news@acteropharma.com

06/08/2018

ACTERO WELCOMED DISTINGUISHED ONCOLOGISTS FOR A SITE VISIT

On 2nd August, renowned oncologists of Iran visited Actero manufacturing facility located in Alborz province. In this ceremony, distinguished oncologists visited the production line of Acteo and were introduced to current and future Actero products.

“It is our great honor to welcome distinguished oncologists to our manufacturing facility and let them witness our potential and commitment to manufacture high-quality oncology products.”

Dr. Tiam Esfahani, Sales and Marketing Director

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

15/07/2018

ACTERO RECEIVES PRIZE ON THE NATIONAL DAY OF INDUSTRIES AND MINES

Actero received a prize from the regional government of the Province of Alborz where the plant is situated. The Province of Alborz and the Ministry of Industry and Mines awarded eminent entrepreneurs in different sectors and recognized the importance of the industrial infrastructure in Iran.

“In Actero we are committed to local manufacturing and our international partners will continue investing resources to produce high-quality products through technology transfer”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

11/07/2018

DR. ASGHARI THE DEPUTY MINISTER OF HEALTH AND CHAIRMAN OF IRANIAN FDA VISITED ACTERO MANUFACTURING PLANT

Dr. Asghari, deputy minister, Dr. Borandegi, director of pharmaceutical products in the FDA and Dr. Sheibani Chairman of Iranian Pharma syndicate among other officials honored Actero with their presence and could witness firsthand the progress of the plant.

“It is a pleasure to welcome our guests in Actero for this progress review. In less than one month, the Solid Dosage Form manufacturing line will start production and oncology products like Capecitabine ACTe will be produced locally”

Dr. Ravindra Babu, Plant Head

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

15/04/2018

ACTERO LAUNCHES DOXORUBICIN ACTE AND ETOPOSIDE ACTE

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market. Doxorubicin ACTe 10mg and 50mg and Etoposide ACTe 100mg/5ml. Doxorubicin ACTe 10mg and 50mg injections are the generic version of Adriamycin, a chemotherapy medication used to treat a broad range of cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. Etoposide ACTe 100mg/5ml injections are the generic version of Etopophos, a chemotherapy medication used to treat a broad range of cancers including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer.

“Doxorubicin ACTe and Etoposide ACTe are the two latest products in our growing oncology portfolio. With these new additions, we aim to gain the trust of all stakeholders and continue building a portfolio where every Actero medicine stands for reliability.”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

20/12/2017

ACTERO LAUNCHES CAPECITABINE ACTE 500MG

Actero Middle East is pleased to announce the launch of its first product to the Iranian market. This launch is a milestone for our young company but it is only the first step towards building our oncology portfolio. Capecitabine ACTe 500mg tablets are equivalent to Xeloda tablets, a chemotherapy medication used to treat breast cancer, gastric cancer and colorectal cancer.

“The approval and launch of Capecitabine ACTe is a good news for oncologists and patients that will have access to a wider range of quality products to choose from. We aim to make our products available in the market and hope to create more competition based solely on quality and let doctors make their choice.”

Dr. Tiam Esfahani, Sales and Marketing Director

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com